TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

TuHURA Biosciences will outline its late-stage immuno-oncology pipeline in a fireside chat at the H.C. Wainwright Global Investment Conference.

Rhea-AI Summary

TuHURA Biosciences (HURA) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York on Monday, September 14 at 4:00 p.m. ET.

The presentation will be a fireside chat with associated 1x1 meetings. The company provides online registration for live viewing, and an archived webcast of the fireside chat will be made available on the Events page in the investor section of TuHURA’s website.

TuHURA is a Phase 3 immuno-oncology company focused on overcoming primary and acquired resistance to cancer immunotherapy. Its lead candidate, IFx-2.0, is in a randomized, placebo-controlled Phase 3 registration trial as an adjunct to Keytruda in first-line advanced or metastatic Merkel Cell Carcinoma, and it is also advancing TBS-2025 and Delta Opioid Receptor-based ADC programs.

Key Terms

immuno-oncology, placebo-controlled, mAb, ADCs

4 terms

immuno-oncology medical

"a Phase 3 immuno-oncology company developing novel therapeutics"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

placebo-controlled medical

"its randomized placebo-controlled Phase 3 registration trial"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

mAb medical

"a VISTA inhibiting mAb moving into dose escalation"

A mAb (monoclonal antibody) is a lab-made protein designed to recognize and bind a specific target on cells or pathogens, like a custom-made key that fits one lock. Investors care because mAbs are often developed as therapies or diagnostic tools whose clinical trial results, regulatory approvals, production capacity, and patent status can drive significant revenue swings and affect a company’s valuation and risk profile.

ADCs medical

"first-in-class, bi-specific, bi-functional antibody drug conjugates (ADCs)"

Antibody-drug conjugates (ADCs) are targeted cancer medicines that combine an antibody, which seeks out specific markers on tumor cells, with a powerful drug payload that is released once the antibody binds its target. Think of them as a guided missile that delivers a toxic package directly to diseased cells to limit harm to healthy tissue. Investors watch ADC news closely because clinical trial results, manufacturing complexity and regulatory decisions can sharply change a biotech company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY. 

H.C. Wainwright 28th Annual Global Investment Conference
Date:	Monday, September 14th
Time:	4:00pm ET
Format:	Fireside Chat & 1x1 Meetings

To register and view the presentation, please CLICK HERE.

An archived webcast of the Fireside Chat will be available on the Events Page in the investor section of TuHURA's website.

About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.

TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is enrolling patients in its randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

In addition to its innate immune agonist product candidates, TuHURA is developing TBS-2025, a VISTA inhibiting mAb moving into dose escalation/optimization Phase 1b trial in mutNPM1 r/r AML, a molecularly defined subgroup representing approximately 35% of patients with AML. TuHURA is also leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific, bi-functional antibody drug conjugates (ADCs) targeting MDSCs to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.

Investor Contact: 
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-to-present-at-the-hc-wainwright-28th-annual-global-investment-conference-302870396.html

SOURCE TuHURA Biosciences, Inc.

FAQ

When and in what format will TuHURA Biosciences present at the H.C. Wainwright conference?

The TuHURA Biosciences presentation is scheduled for Monday, September 14 at 4:00 p.m. ET. It will be held as a fireside chat, with additional 1x1 meetings during the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY.

How can investors access TuHURA Biosciences’ conference presentation and replay?

Investors can register and view the presentation through an online registration link provided by TuHURA. An archived webcast of the fireside chat will be available after the event on the Events Page in the investor section of TuHURA’s website.

What is TuHURA Biosciences’ lead clinical program IFx-2.0?

IFx-2.0 is TuHURA’s lead innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company is enrolling patients in a randomized, placebo-controlled Phase 3 registration trial of IFx-2.0 given as an adjunctive therapy to Keytruda (pembrolizumab) compared with Keytruda plus placebo in first-line treatment of advanced or metastatic Merkel Cell Carcinoma.

What other pipeline programs is TuHURA Biosciences advancing?

TuHURA is developing TBS-2025, a VISTA-inhibiting monoclonal antibody moving into dose escalation/optimization Phase 1b in mutNPM1 relapsed/refractory AML, a molecularly defined subgroup that represents approximately 35% of AML patients. The company is also leveraging its Delta Opioid Receptor technology to create first-in-class, bi-specific, bi-functional antibody drug conjugates targeting myeloid-derived suppressor cells (MDSCs) to reduce immune suppression in the tumor microenvironment and address acquired resistance to checkpoint inhibitors and cellular therapies.